Loading…
PEVANTI is a brand name for Prednisolone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Prednisolone is indicated for the treatment and/or suppression of inflammatory and allergic disorders.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology In adults and the elderly:
The lowest effective dose should be used for the minimum period in order to minimise side effects.
Paediatric population:
Prednisolone should be used only when specifically indicated, in a minimum dosage and for the shortest possible time. The initial dosage of Prednisolone Tablets may vary from 5mg to 60mg or more depending on the disorder being treated.
Divided daily dosage is usually used. The following therapeutic guidelines should be kept in mind for all therapy with corticosteroids: Corticosteroids are palliative symptomatic treatment by virtue of their anti- inflammatory effects; they are never curative.
The appropriate individual dose must be determined by trial and error and must be re-evaluated regularly according to activity of the disease. As corticosteroid therapy becomes prolonged and as the dose is increased, the incidence of disabling side-effects increases.
In general, initial dosage shall be maintained or adjusted until the anticipated response is observed. The dose should be gradually reduced until the lowest dose which will maintain an adequate clinical response is reached. Use of the lowest effective dose may also minimise side-effects (see 'Special warnings and special precautions for use').
5mg prednisolone or equivalent) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced.
Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids but there is uncertainty about hypothalamic-pituitary-adrenal (HPA) suppression, the dose of corticosteroid may be reduced rapidly to physiological doses.
5mg of prednisolone is reached, dose reduction should be slower to allow the HPA-axis to recover. Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is appropriate if it is considered that the disease is unlikely to relapse.
Abrupt withdrawal of doses of up to 40mg daily of prednisolone, or equivalent for 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less: • patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.
A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported.
Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is Not known.
4). Adverse reactions are listed as per System Organ Class. The following adverse reactions have been observed at the frequencies defined using the following convention: Not known: cannot be estimated from the available data. 4). 4) Ear and labyrinth disorders Vertigo Cardiac disorders Congestive heart failure in susceptible patients Vascular disorders Thromboembolism, hypertension Gastrointestinal disorders Dyspepsia, nausea, peptic ulcer with perforation and haemorrhage, abdominal distension, abdominal pain, diarrhoea, oesophageal ulceration, oesophageal candidiasis, pancreatitis acute Skin and subcutaneous tissue disorders Hirsutism, skin atrophy, bruising, skin striae, telangiectasia, acne, hyperhidrosis, may suppress reactions to skin tests, pruritis, rash, urticaria Musculoskeletal and connective tissue disorders Myopathy, osteoporosis, vertebral and long bone fractures, avascular osteonecrosis, myalgia Renal and urinary disorders Scleroderma renal crisis* Reproductive system and breast disorders Menstrual irregular and amenorrhoea General disorders and administration site conditions Impaired healing, withdrawal symptoms**, fatigue, malaise.
Investigations Weight increased ,increased intra-ocular pressure Injury, poisoning and procedural complications Tendon rupture *Scleroderma renal crisis Amongst the different subpopulations the occurrence of scleroderma renal crisis varies.
1. Systemic infections unless specific anti-infective therapy is employed. Patients with ocular herpes simplex due to the possibility of perforation. 4 Special warnings and precautions for use A patient information leaflet should be supplied with this product.
Patients should carry “steroid treatment” cards which give clear guidance on the precautions to be taken to minimise risk and provide details of prescriber, drug, dosage and duration of treatment. 8). Symptoms typically emerge within a few days or weeks of starting the treatment.
5 pharmacokinetic interactions that can increase the risk of side effects), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.
Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.
Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.
Caution is necessary when corticosteroids, including prednisolone, are prescribed to patients with the following conditions and frequent patient monitoring is necessary: • Diabetes mellitus or in those with a family history of diabetes.
• Glaucoma or in those with a family history of glaucoma. • Hypertension or congestive heart failure. • Liver failure. • Epilepsy. • Osteoporosis: This is of special importance in post-menopausal females who are at particular risk. • Patients with a history of severe affective disorders and particularly those with a previous history of corticosteroid induced psychoses.
1. Systemic infections unless specific anti-infective therapy is employed. Patients with ocular herpes simplex due to the possibility of perforation.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Prednisolone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
• when a short course has been prescribed within one year of cessation of long- term therapy (months or years). • patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy. • patients receiving doses of systemic corticosteroid greater than 40mg daily of prednisolone (or equivalent).
• patients repeatedly taking doses in the evening. 4) If there is lack of a satisfactory clinical response to Prednisolone Tablets, the drug should be gradually discontinued and the patient transferred to alternative therapy. Intermittent dosage regimen A single dose of Prednisolone Tablets in the morning on alternate days or at longer intervals is acceptable therapy for some patients.
When this regimen is practical, the degree of pituitary-adrenal suppression can be minimised. Specific dosage guidelines The following recommendations for some corticosteroid-responsive disorders are for guidance only. Acute or severe disease may require initial high dose therapy with reduction to the lowest effective maintenance dose as soon as possible.
5mg daily during chronic treatment. Allergic and skin disorders Initial doses of 5-15mg daily are commonly adequate. Collagenosis Initial doses of 20-30mg daily are frequently effective. Those with more severe symptoms may require higher doses.
Rheumatoid arthritis The usual initial dose is 10-15mg daily. The lowest daily maintenance dose compatible with tolerable symptomatic relief is recommended. Blood disorders and lymphoma An initial daily dose of 15-60mg is often necessary with reduction after an adequate clinical or haematological response.
Higher doses may be necessary to induce remission in acute leukaemia. 4'). 4). Alternate day dosage is preferable where possible.
Method of administration:
Oral The daily dose should be taken in the morning after breakfast. For further information with reference to dosage see section
The highest risk has been reported in patients with diffuse systemic sclerosis. 2). A steroid “withdrawal syndrome” seemingly unrelated to adrenocortical insufficiency may also occur following abrupt discontinuance of glucocorticoids.
This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.
Additional side effects in children and adolescents Suppression of the hypothalamo-pituitary adrenal axis particularly in times of stress, as in trauma, surgery or illness, growth suppression in infancy, childhood and adolescence. Raised intracranial pressure with papilloedema (pseudotumor cerebri) in children, usually after treatment withdrawal.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
• Peptic ulceration. • Previous steroid myopathy. • Glucocorticoids should be used cautiously in patients with myasthenia gravis receiving anticholinesterase therapy. • Because cortisone has been reported rarely to increase blood coagulability and to precipitate intravascular thrombosis, thromboembolism, and thrombophlebitis, corticosteroids should be used with caution in patients with thromboembolic disorders.
• Renal insufficiency. • Tuberculosis: Those with a history of, or X-ray changes characteristic of tuberculosis. The emergence of active tuberculosis can, however, be prevented by the prophylactic use of antituberculous therapy. • Recent myocardial infarction (rupture).
• Chickenpox: Chickenpox is of particular concern since this normally minor illness may be fatal in immunosuppressed patients. Patients (or parents of children) without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention.
Passive immunisation with varicella/zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are receiving systemic corticosteroids or who have used them within the previous 3 months; this should be given within 10 days of exposure to chickenpox.
If a diagnosis of chickenpox is confirmed, the illness warrants special care and urgent treatment. Corticosteroids should not be stopped and the dose may need to be increased. • Measles: Patients are advised to avoid exposure to measles, medical advice should be sought if exposure occurs.
Prophylaxis with intramuscular normal immunoglobulin may be needed. • Suppression of the inflammatory response and immune function increases the susceptibility to infections and their severity. The clinical presentation may often be atypical and serious infections such as septicaemia and tuberculosis may be masked and may reach an advanced stage before being recognised.
• The effect of corticosteroids may be enhanced in patients with hypothyroidism in those with chronic liver disease with impaired hepatic function. • Live vaccines should not be given to individuals with impaired immune responsiveness.
The antibody response to other vaccines may be diminished. • Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Visual disturbance Visual disturbance may be reported with systemic and topical corticosteroid use.
If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Scleroderma renal crisis Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more prednisolone.
Blood pressure and renal function (s-creatinine) should therefore be routinely checked. When renal crisis is suspected, blood pressure should be carefully controlled. 5mg prednisolone or equivalent) for greater than 3 weeks, withdrawal should not be abrupt.
How dose reduction should be carried out depends largely on […]